Bensi C, Belli S, Paradiso D, Lomurno G
Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy.
Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy.
Int J Oral Maxillofac Surg. 2018 Jul;47(7):923-932. doi: 10.1016/j.ijom.2018.03.016. Epub 2018 Apr 5.
Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban; DOACs) have been introduced to improve safety and superior therapeutic value compared to their predecessors such as warfarin or enoxaparin. The aim of this systematic review and meta-analysis was to assess the postoperative bleeding risk of DOACs during oral surgery procedures. Systematic searches were performed in electronic databases including PubMed, Scopus, Web of Science and Cochrane Library. Thirteen studies were included in the qualitative synthesis: two retrospective case-control studies, five prospective case-control studies, three cross-sectional studies, two case series and a case report; while only six studies were statistically analysed. The risk ratio of postoperative bleeding in DOACs patients was significantly greater than in healthy patients (3.04; 95% confidence interval (CI)=1.31-7.04). This is especially true for rivaroxaban (4.13; 95% CI=1.25-13.69), and less so for dabigatran which presented a risk ratio similar to that of healthy patients (1.00; 95% CI=0.21-4.82). However, further research is required to support these results. Both apixaban and edoxaban were excluded from statistical analysis due to the lack of clinical studies.
直接口服抗凝剂(达比加群、利伐沙班、阿哌沙班和依度沙班;DOACs)已被引入,与华法林或依诺肝素等前代药物相比,具有更高的安全性和治疗价值。本系统评价和荟萃分析的目的是评估口腔手术过程中DOACs的术后出血风险。在包括PubMed、Scopus、科学网和考克兰图书馆在内的电子数据库中进行了系统检索。定性综合分析纳入了13项研究:2项回顾性病例对照研究、5项前瞻性病例对照研究、3项横断面研究、2项病例系列研究和1项病例报告;而只有6项研究进行了统计学分析。DOACs患者术后出血的风险比显著高于健康患者(3.04;95%置信区间(CI)=1.31-7.04)。利伐沙班尤其如此(4.13;95%CI=1.25-13.69),而达比加群的风险比与健康患者相似(1.00;95%CI=0.21-4.82),情况稍好。然而,需要进一步的研究来支持这些结果。由于缺乏临床研究,阿哌沙班和依度沙班均未纳入统计分析。